The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.
A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...